InvestSMART

Living Cell Technologies Limited (ASX: LCT) - Announcements

- Current share price for LCT : $0.014

ASX company news and announcements for Living Cell Technologies Limited (LCT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Living Cell Technologies Limited (LCT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Living Cell Technologies Limited (LCT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Living Cell Technologies Limited (LCT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 Appendix 4C - quarterly 30 Apr 2012 9:44AM $0.060 $0.014 fallen by 76.67%
$23 LCT Presents Novel Parkinson`s Disease Treatment Results 21 Mar 2012 9:09AM $0.090 $0.014 fallen by 84.44%
$23 LCT announces Share Purchase Plan 20 Mar 2012 9:11AM $0.086 $0.014 fallen by 83.72%
$23 LCT granted E.U. Patent for tissue engineering 28 Feb 2012 4:07PM $0.068 $0.014 fallen by 79.41%
$23 LCT completes pre-clinical studies of NTCELL in Parkinson`s 28 Feb 2012 3:44PM $0.068 $0.014 fallen by 79.41%
$23 Price query response 16 Feb 2012 4:56PM $0.069 $0.014 fallen by 79.71%
$23 LCT granted USA Patent for Auckland Island Pigs 2 Feb 2012 10:36AM $0.055 $0.014 fallen by 74.55%
$23 Appendix 4C - quarterly 27 Jan 2012 12:35PM $0.052 $0.014 fallen by 73.08%
$23 LCT appoints Chief Executive 28 Dec 2011 9:33AM $0.046 $0.014 fallen by 69.57%
$23 Settlement of $A50 million JV to commercialise DIABECELL 2 Nov 2011 8:47AM $0.080 $0.014 fallen by 82.50%
$23 Appendix 4C - quarterly 28 Oct 2011 2:19PM $0.060 $0.014 fallen by 76.67%
$23 Otsuka commits $A25 million to JV with LCT 19 Oct 2011 10:06AM $0.105 $0.014 fallen by 86.67%
$23 Research collaboration with Centocor terminated 4 Oct 2011 9:01AM $0.046 $0.014 fallen by 69.57%
$23 Preliminary Final Report 25 Aug 2011 2:52PM $0.050 $0.014 fallen by 72%
$23 First Argentina Patients Implanted 22 Aug 2011 9:20AM $0.058 $0.014 fallen by 75.86%
$23 Appendix 4C - quarterly 29 Jul 2011 12:48PM $0.056 $0.014 fallen by 75%
$23 SpringTree facility terminated by mutual consent 26 Jul 2011 9:02AM $0.060 $0.014 fallen by 76.67%
$23 LCT Enrols First Patients in DIABECELL Argentina Trial 27 Jun 2011 10:18AM $0.061 $0.014 fallen by 77.05%
$23 Resignation and Appointment of acting CEO 24 Jun 2011 3:42PM n/a $0.014 n/a
$23 SpringTree tranches paused until July 5 May 2011 3:02PM $0.099 $0.014 fallen by 85.86%
$23 LCT Approved for DIABECELL Clinical Trial in Argentina 3 May 2011 2:26PM $0.110 $0.014 fallen by 87.27%
$23 Appendix 4C - quarterly 20 Apr 2011 9:24AM $0.125 $0.014 fallen by 88.80%
$23 LCT and Otsuka of Japan Share Common DIABECELL Vision 12 Apr 2011 11:08AM $0.115 $0.014 fallen by 87.83%
$23 Appendix 4D and Half Year Accounts 25 Feb 2011 11:39AM $0.060 $0.014 fallen by 76.67%
$23 LCTs encapsulating technology granted key Australian patent 24 Feb 2011 10:26AM $0.097 $0.014 fallen by 85.57%

426 - 450 of 584 results

Page 18 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.